PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32558295-3 2020 Exploring these mechanisms of resistance, we found that EML4-ALK cells parental or resistant to crizotinib, ceritinib or alectinib are remarkably sensitive to inhibition of CDK7/12 with THZ1 and CDK9 with alvocidib or dinaciclib. dinaciclib 218-228 cyclin dependent kinase 9 Homo sapiens 195-199 34972202-2 2022 The multicohort, phase 1 KEYNOTE-155 study evaluated the safety and antitumor activity of the PD-1 inhibitor pembrolizumab plus the CDK9 inhibitor dinaciclib in patients with relapsed or refractory (rr) chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM). dinaciclib 147-157 cyclin dependent kinase 9 Homo sapiens 132-136 33686114-6 2021 We found that dinaciclib-triggered apoptosis is triggered by CDK9 inhibition and the resultant reduction in RNA pol II phosphorylation, which leads to the downregulation of the oncogenic marker MYC, and the anti-apoptotic protein MCL-1. dinaciclib 14-24 cyclin dependent kinase 9 Homo sapiens 61-65 32375399-8 2020 Dinaciclib was shown to drastically enhance EV-T killing effects on cancer lines that express good levels of death receptor (DR) 5, which are associated with suppression of CDK1, CDK9 and anti-apoptotic proteins. dinaciclib 0-10 cyclin dependent kinase 9 Homo sapiens 179-183 28361959-3 2017 In this report, we show that the CDKs inhibitor, Dinaciclib, selectively eliminates iPS cells without affecting the viability of cardiac cells. dinaciclib 49-59 cyclin dependent kinase 9 Homo sapiens 33-37 28361959-7 2017 Dinaciclib also inhibited the phosphorylation of Serine 2 of the C-terminal domain of RNA Polyemrase II through CDK9 inhibition. dinaciclib 0-10 cyclin dependent kinase 9 Homo sapiens 112-116 27378523-0 2016 Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity. dinaciclib 23-33 cyclin dependent kinase 9 Homo sapiens 90-94 27486754-0 2016 Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer. dinaciclib 43-53 cyclin dependent kinase 9 Homo sapiens 14-39 27486754-7 2016 These data support the importance of CDK9, in addition to CDK1, in mediating the growth inhibitory effect of dinaciclib in TNBC. dinaciclib 109-119 cyclin dependent kinase 9 Homo sapiens 37-41 27378523-4 2016 Here we show that a novel multiple-CDK inhibitor, dinaciclib (SCH727965, MK-7965), exhibits potent anti-proliferative effects on a panel of NB cell lines by blocking the activity of CDK2 and CDK9. dinaciclib 50-60 cyclin dependent kinase 9 Homo sapiens 191-195 27378523-4 2016 Here we show that a novel multiple-CDK inhibitor, dinaciclib (SCH727965, MK-7965), exhibits potent anti-proliferative effects on a panel of NB cell lines by blocking the activity of CDK2 and CDK9. dinaciclib 62-71 cyclin dependent kinase 9 Homo sapiens 191-195 27378523-4 2016 Here we show that a novel multiple-CDK inhibitor, dinaciclib (SCH727965, MK-7965), exhibits potent anti-proliferative effects on a panel of NB cell lines by blocking the activity of CDK2 and CDK9. dinaciclib 73-80 cyclin dependent kinase 9 Homo sapiens 191-195 26766294-5 2016 Clinical studies of the drugs flavopiridol, dinaciclib, seliciclib, SNS-032 and RGB-286638 used as CDK9 inhibitors are also reviewed, with their additional targets and their relative IC50 values. dinaciclib 44-54 cyclin dependent kinase 9 Homo sapiens 99-103 25578475-0 2015 CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo. dinaciclib 19-29 cyclin dependent kinase 9 Homo sapiens 0-4 25882699-3 2015 Here we explore drugs that cause loss of MCL1, particularly the potent new cyclin-dependent kinase inhibitor dinaciclib, which knocks down MCL1 by inhibiting CDK9. dinaciclib 109-119 cyclin dependent kinase 9 Homo sapiens 158-162 25962959-2 2015 Dinaciclib, a novel small molecule inhibitor of CDK1, CDK2, CDK5 and CDK9, is assessed in clinical trials for the treatment of several types of cancers. dinaciclib 0-10 cyclin dependent kinase 9 Homo sapiens 69-73 25395429-2 2015 Dinaciclib is a novel potent small molecule inhibitor of cyclin-dependent kinases (CDK)1, CDK2, CDK5, and CDK9. dinaciclib 0-10 cyclin dependent kinase 9 Homo sapiens 106-110 25217392-1 2014 PURPOSE: Dinaciclib is a novel selective inhibitor of cyclin-dependent kinase (CDK)1, CDK2, CDK5, and CDK9. dinaciclib 9-19 cyclin dependent kinase 9 Homo sapiens 102-106 23053255-1 2012 PURPOSE: Dinaciclib, a selective inhibitor of cyclin-dependent kinase (CDK) 1, CDK2, CDK5, and CDK9, is metabolized via CYP3A4. dinaciclib 9-19 cyclin dependent kinase 9 Homo sapiens 95-99